Pyrojas

Pyrojas is a private, pre-clinical stage biotech founded in 2016 and based in San Diego, CA, focused on next-generation cancer vaccines. Its core technology, PyroCells, is an autologous whole tumor cell vaccine designed to overcome tumor heterogeneity by presenting the full antigenic landscape to the immune system, aiming to prevent relapse. With backing from the National Cancer Institute (NCI), Bristol Myers Squibb, and venture capital, and guided by a world-class scientific advisory board, the company is preparing to translate its promising pre-clinical results into human trials. Pyrojas also offers a licensing opportunity for its PyroTIMER technology, a T cell function booster.

PyroCells: An autologous whole tumor cell vaccine platform engineered to present the full antigenic landscape of a patient's cancer, stimulating a broad, durable T cell response to prevent relapse. Features high-efficiency non-viral engineering and rapid manufacturing.

Pyrojas competes in the personalized cancer vaccine arena against companies like BioNTech, Moderna, and Gritstone bio, which are advancing mRNA neoantigen vaccines. It also competes with other whole-cell or dendritic cell vaccine approaches. Its key differentiator is the use of the entire engineered tumor cell as the immunogen to overcome heterogeneity, but it must prove this translates to clinical superiority or complementarity.